Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278377 | 0.85 | TAAR1 (0.52) | ADRA1ATAAR1KDM4EATMCSNK2A1 | |
| SCHEMBL26037611 | 0.85 | GABRA1 (0.55) | GABRA1GABRB2ALOX5ADRA1ATAAR1 | |
| Hydrochloric Acid SCHEMBL6768219 | 0.84 | TAAR1 (0.50) | ADRA1ATAAR1KDM4EATMCSNK2A1 | |
| SCHEMBL28131611 | 0.79 | ALOX5 (0.54) | GABRA1GABRB2ALOX5 | |
| SCHEMBL16973529 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2ALOX5GABRA5GABRA3 | |
| SCHEMBL16930050 | 0.79 | SIGMAR1 (0.48) | GABRA1GABRB2ALOX5GABRA5GABRA3 | |
| SCHEMBL8705798 | 0.79 | TAAR1 (0.64) | ADRA1ATAAR1KDM4EATM | |
| SCHEMBL11290729 | 0.78 | GABRA1 (0.55) | GABRA1GABRB2ALOX5GABRA5GABRA3 | |
| SCHEMBL9886085 | 0.78 | GABRA1 (0.55) | GABRA1GABRB2ALOX5TAAR1GABRA5 | |
| SCHEMBL44393 | 0.77 | ATM (0.70) | TAAR1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377481-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2017214286-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377481-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NOS1, NOS3, NOS2 | GABRA1 1359/4885GABRB2 495/4885ALOX5 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.